Periocular basal cell carcinoma: recurrence risk factors/when to reoperate?
- PMID: 33603611
- PMCID: PMC7874855
- DOI: 10.5114/ada.2020.102109
Periocular basal cell carcinoma: recurrence risk factors/when to reoperate?
Abstract
Introduction: The aim of periocular basal cell carcinoma (BCC) surgery is radical excision of the tumour while maintaining eyelid functionality and facial aesthetics. Differences in management of the patients after excision of eyelid BCC with a narrow margin are described in the literature.
Aim: This study concerns the correlation between the recurrence rate in the periorbital area and the narrow safety margin of excision in the histopathological report with respect to various clinical and histopathological features.
Material and methods: A retrospective non-randomized analysis was conducted on 158 patients with BCC of the periorbital area. These patients were operated on between January 2002 and December 2016. A database was created, comprised of patient age, sex, location of the lesion, TNM, method of reconstruction, result of the histopathological examination, date and location of the recurrence.
Results: In 66 (41.77%) patients BCC was radically removed. In 50 (31.65%) patients BCC was removed with a narrow margin and in 42 (26.58%) cases, radical excision was not achieved. The recurrence rate was significantly higher in the aggressive BCC group compared to those with non-aggressive BCC (p = 0.004). The recurrence-free rate for non-aggressive subtypes was 98.11% in both the first and fifth years, but in aggressive subtypes it was 89.06% in the first year but fell to 80.16% in the fifth year.
Conclusions: An aggressive subtype of BCC significantly influences the risk of non-radical excision of the lesion. Aggressive BCC subtypes should have more frequent check-ups. There is no need to reoperate patients with a narrow margin of BCC excision.
Keywords: basal cell carcinoma; incomplete excision; periocular; recurrence rate; risk factors.
Copyright: © 2021 Termedia Sp. z o. o.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Periocular basal cell carcinoma results and surgical outcome during a 5-year period in a larger Danish population.BMC Ophthalmol. 2022 Jun 28;22(1):282. doi: 10.1186/s12886-022-02494-9. BMC Ophthalmol. 2022. PMID: 35761210 Free PMC article.
-
Recurrence rates of periocular basal cell carcinoma following intra-operative en-face frozen section margin controlled excision.Ir J Med Sci. 2024 Jun;193(3):1209-1213. doi: 10.1007/s11845-024-03620-w. Epub 2024 Jan 30. Ir J Med Sci. 2024. PMID: 38289579
-
Histological subtypes of periocular basal cell carcinoma.Clin Exp Ophthalmol. 2014 Sep-Oct;42(7):603-7. doi: 10.1111/ceo.12298. Epub 2014 Mar 11. Clin Exp Ophthalmol. 2014. PMID: 24533627 Review.
-
The Impact of Pathological Margins on Basal Cell Carcinoma Recurrence: Does a Millimetre Matter?Cureus. 2025 Apr 17;17(4):e82428. doi: 10.7759/cureus.82428. eCollection 2025 Apr. Cureus. 2025. PMID: 40385766 Free PMC article.
-
Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.Onco Targets Ther. 2017 May 8;10:2483-2489. doi: 10.2147/OTT.S130371. eCollection 2017. Onco Targets Ther. 2017. PMID: 28507440 Free PMC article. Review.
Cited by
-
Reconstructive Techniques Following Malignant Eyelid Tumour Excision-Our Experience.J Clin Med. 2024 Oct 14;13(20):6120. doi: 10.3390/jcm13206120. J Clin Med. 2024. PMID: 39458069 Free PMC article.
-
Risk Factors for Orbital Invasion in Malignant Eyelid Tumors, Is Orbital Exenteration Still Necessary?J Clin Med. 2024 Jan 26;13(3):726. doi: 10.3390/jcm13030726. J Clin Med. 2024. PMID: 38337420 Free PMC article.
-
Comparison of Socio-demographic Characteristics, Tumour Features, and Surgical Treatment Outcomes in Phenotypic Variants of Basal Cell Carcinoma.Indian J Dermatol. 2024 May-Jun;69(3):212-220. doi: 10.4103/ijd.ijd_755_23. Epub 2024 Jun 26. Indian J Dermatol. 2024. PMID: 39119316 Free PMC article.
-
Aggressive subtypes in basal cell carcinomas might need different treatment and follow-up due to the higher risk of surgically uncontrollable recurrences.Graefes Arch Clin Exp Ophthalmol. 2025 Jul;263(7):2033-2040. doi: 10.1007/s00417-025-06807-8. Epub 2025 Mar 26. Graefes Arch Clin Exp Ophthalmol. 2025. PMID: 40140076 Free PMC article.
-
Role of Bcl-2, p53, and Ki-67 expression in basal cell carcinoma and their association with aggressive and non-aggressive histological phenotypes.Postepy Dermatol Alergol. 2022 Jun;39(3):517-523. doi: 10.5114/ada.2022.117598. Epub 2022 Jul 14. Postepy Dermatol Alergol. 2022. PMID: 35950121 Free PMC article.
References
-
- NCCN Clinical Practice Guidelines in Oncology Head and Neck Cancer, version 1. 2019. 2019. Jan 29,
-
- Bichakjian CK, John YS. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78:560–78. - PubMed
LinkOut - more resources
Full Text Sources